Join the Oncology Voice Network. Join for Free
The Power of Commercial Leadership in Oncology

The Power of Commercial Leadership in Oncology


Share This Article


Summary

Discover how commercial leadership, collaboration, and clear communication shape success in oncology—and why patients depend on it.

 

What does it mean to be the true “voice of commercial” in oncology, and why does it matter more than ever?

 

In this episode of Oncology Voice Network Podcast, join Dr. Kirk Shepard as he welcomes Daniel Switzer, Head of U.S. Oncology at Daiichi Sankyo, for a revealing look inside the commercial engine that drives cancer innovation from the lab all the way to the patient. With two decades of leading launches, transformations, and cross-functional teams, Daniel Switzer shares his most pivotal moments, from high-stakes encounters with patients to standing ovations at ASCO Congress.

 

Discover why commercial is about so much more than sales, how ethical responsibility and clear alignment can truly change outcomes, and what happens when teams get it wrong. Daniel Switzer discusses breaking down silos, building bridges with R&D, and the necessity of early, unified collaboration in launching life-changing therapies. Plus, hear why the Oncology Voice Network and industry-wide learning are the next frontiers in elevating patient care.

 

Whether you're in pharma, research, or just passionate about innovation, this episode will reframe what commercial leadership means in today’s oncology world.

 

Tune in now and get inspired to bridge the gaps that matter most.

 

Watch on YouTube

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Article
Transforming oncology: Five frontiers driving progress in cancer care
Partner Avatar iNIZIO

Transforming oncology: Five frontiers driving progress in cancer care

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Article
Virtual Oncology MSL Team Increases KOL Engagement by 120%
Partner Avatar iNIZIO

Virtual Oncology MSL Team Increases KOL Engagement by 120%

Explore OVN